An Analysis of Covid-19 Effect on Patients With Colorectal Cancer - Follow-up Regarding Tumour Stage, Neoadjuvant Treatment, Delay and Long-term Survival

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Colorectal cancer is common with an annual prevalence of 6000. The majority can be cured and the five year survival rate is over 60%. In december 2019 reports came in about SARS-Cov-2, which later was named Covid-19. The World Health Organization classified it as a pandemic in March 2020. In Sweden the number of patients with Covid-19 increased mainly in the urban areas in March 2020. Care for patients with other diseases were affected and local changes from guidelines were adopted. In some regions and countries the indications for adjuvant and neoadjuvant treatment for colorectal cancer were somewhat changed. The number of patients diagnosed with colorectal cancer also decreased, as well as other types of cancer. The true effect on outcome with a delayed diagnosis remains unknown. The aim of this study is to evaluate the effects of the Covid-19 pandemic on the diagnosis, treatment and survival of patients with colorectal cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Rectal cancer diagnosis 2019-2022

Locations
Other Locations
Sweden
Dept. of Surgery, Sahlgrenska University Hospital/Ostra
RECRUITING
Gothenburg
Contact Information
Primary
Eva Angenete, MD. PhD
eva.angenete@vgregion.se
0760514441
Backup
Anette Wedin, RN
anette.wedin@vgregion.se
Time Frame
Start Date: 2022-02-15
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 8000
Treatments
Patients diagnosed before, during or after the pandemic
Patients with rectal cancer
Related Therapeutic Areas
Sponsors
Leads: Sahlgrenska University Hospital

This content was sourced from clinicaltrials.gov